BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33299109)

  • 21. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.
    Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V
    PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma.
    Nishio J; Althof PA; Bailey JM; Zhou M; Neff JR; Barr FG; Parham DM; Teot L; Qualman SJ; Bridge JA
    Lab Invest; 2006 Jun; 86(6):547-56. PubMed ID: 16607381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
    Jothi M; Mal M; Keller C; Mal AK
    Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG
    Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
    J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of FOXO1 immunohistochemistry for rhabdomyosarcoma classification.
    Rutland CD; Gedallovich J; Wang A; Zdravkovic S; Varma S; Hornick JL; Charville GW
    Histopathology; 2023 Jul; 83(1):49-56. PubMed ID: 36860202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma.
    Hosoi H; Kakazu N; Konishi E; Tsuchihashi Y; Hada S; Amaya E; Nakabayahi Y; Misawa-Furihata A; Tabata-Maruyama H; Iehara T; Sugimoto T; Yamane H; Yamasaki M; Shiwaku K; Yanagisawa A; Ono M; Tokiwa K; Iwai N; Hashiba M; Abe T; Sawada T
    Cancer Genet Cytogenet; 2009 Mar; 189(2):98-104. PubMed ID: 19215790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
    Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
    Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
    Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
    Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
    Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E
    Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
    Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
    Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
    Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
    Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
    Sullivan LM; Atkins KA; LeGallo RD
    Am J Surg Pathol; 2009 May; 33(5):775-80. PubMed ID: 19145202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
    Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
    Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.